Hantz Financial Services Inc. Decreases Position in Abbott Laboratories $ABT

Hantz Financial Services Inc. cut its holdings in Abbott Laboratories (NYSE:ABT) by 11.1% in the third quarter, HoldingsChannel reports. The institutional investor owned 239,289 shares of the healthcare product maker’s stock after selling 29,746 shares during the quarter. Hantz Financial Services Inc.’s holdings in Abbott Laboratories were worth $32,050,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of ABT. Ashton Thomas Private Wealth LLC raised its position in shares of Abbott Laboratories by 10.7% in the 3rd quarter. Ashton Thomas Private Wealth LLC now owns 55,630 shares of the healthcare product maker’s stock valued at $7,451,000 after purchasing an additional 5,356 shares during the last quarter. SGL Investment Advisors Inc. increased its stake in Abbott Laboratories by 87.0% during the 3rd quarter. SGL Investment Advisors Inc. now owns 4,975 shares of the healthcare product maker’s stock valued at $616,000 after purchasing an additional 2,314 shares in the last quarter. Westside Investment Management Inc. raised its holdings in shares of Abbott Laboratories by 12.2% in the third quarter. Westside Investment Management Inc. now owns 3,227 shares of the healthcare product maker’s stock worth $432,000 after buying an additional 350 shares during the last quarter. Strengthening Families & Communities LLC raised its holdings in shares of Abbott Laboratories by 3,076.5% in the third quarter. Strengthening Families & Communities LLC now owns 8,799 shares of the healthcare product maker’s stock worth $1,168,000 after buying an additional 8,522 shares during the last quarter. Finally, Cornerstone Planning Group LLC lifted its stake in shares of Abbott Laboratories by 110.0% during the third quarter. Cornerstone Planning Group LLC now owns 2,085 shares of the healthcare product maker’s stock worth $279,000 after buying an additional 1,092 shares during the period. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Citigroup cut their price objective on Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating on the stock in a report on Friday, January 23rd. Evercore ISI cut their price target on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Argus decreased their price objective on shares of Abbott Laboratories from $150.00 to $140.00 in a research note on Tuesday, January 27th. Barclays dropped their price objective on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating on the stock in a report on Monday. Finally, Mizuho raised their target price on shares of Abbott Laboratories from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday, October 14th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus target price of $137.05.

Abbott Laboratories Trading Down 0.4%

Shares of Abbott Laboratories stock opened at $108.95 on Wednesday. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. Abbott Laboratories has a twelve month low of $105.27 and a twelve month high of $141.23. The firm has a market capitalization of $189.45 billion, a PE ratio of 29.29, a P/E/G ratio of 1.74 and a beta of 0.75. The firm’s 50-day moving average price is $122.03 and its 200 day moving average price is $127.24.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.50. The company had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter last year, the firm posted $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, sell-side analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be paid a $0.63 dividend. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date of this dividend is Thursday, January 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio is currently 67.74%.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s CEO made a roughly $2M insider purchase, signaling management’s confidence in the stock amid the pullback; insider buying can support sentiment and is often viewed as a bullish sign by investors. Read More.
• Positive Sentiment: Freedom Capital upgraded ABT to a “Buy,” adding demand-side support from at least one asset manager which can temper downside and attract buyers looking for upgrades. Read More.
• Positive Sentiment: Long-term bullish analysts and dividend-growth commentators highlight Abbott’s Dividend Aristocrat status, strong cash flow and multi-year revenue growth — a reminder of the stock’s longer-term appeal to income and total-return investors. Read More.
• Neutral Sentiment: Abbott’s tie-up with Exact Sciences reshapes its diagnostics footprint even as it signals a strategic pivot; investors will watch integration progress and whether diagnostics can offset nutrition weakness. This is strategically important but will take time to affect results. Read More.
• Neutral Sentiment: Analyst commentary is mixed — some bullish takes and value comparisons (e.g., relative to peers) keep the long-term case alive but do not remove near-term execution risks. Read More.
• Negative Sentiment: FDA is scrutinizing the FreeStyle Libre system and broader quality controls, raising regulatory and remediation risk that could affect device revenue, recall costs or approval timelines — a clear near-term negative for investor sentiment. Read More.
• Negative Sentiment: Abbott warned of profit pressure after missing revenue estimates; pediatric nutrition remains under sustained pressure, which is the primary near-term drag on revenue and margins. Continued weakness in that division is a key reason earnings guidance was tempered. Read More.
• Negative Sentiment: Several brokerages cut price targets recently (Barclays lowered its target to $142 though kept an overweight rating; Daiwa and Leerink trimmed targets to $113 and $119), increasing short-term selling pressure by reducing upside expectations and signaling cautious near-term forecasts. Read More. Read More. Read More.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.